stockportfolio.pro
Indivior Pharmaceuticals, Inc. (INDV)
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqGS
Indivior Pharmaceuticals, Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $901.00M | $1.09B | $1.19B | $1.24B |
| Gross profit | $749.00M | $919.00M | $957.00M | $994.00M |
| Net income | $-53.00M | $2.00M | $-48.00M | $210.00M |
| Net margin | -5.9% | 0.2% | -4.0% | 16.9% |
Source: Indivior Pharmaceuticals, Inc. SEC filings (10-K).
Explore 4 years of Indivior Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track INDV in your portfolio →
About Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Indivior Pharmaceuticals, Inc. — frequently asked questions
What is Indivior Pharmaceuticals, Inc.'s revenue?
Indivior Pharmaceuticals, Inc. (INDV) reported revenue of $1.24B for fiscal year 2025, up 4.3% from the prior year, according to its SEC filings.
Is Indivior Pharmaceuticals, Inc. profitable?
Yes. INDV earned net income of $210.00M in fiscal 2025, a net margin of 16.9%.
What is INDV's P/E ratio?
Indivior Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 19.5 based on the latest data in our nightly-refreshed cache.
How fast is Indivior Pharmaceuticals, Inc. growing?
INDV's revenue grew at roughly 11.2% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Indivior Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.